LACTOLOGY FOUNDATION

Multienzymes (Lipase, Protease, etc.) (ATC A09AA02): Toxicological and Lactation Monograph

ATC Class and General Pharmacology

ATC A09AA02 designates multienzymes (lipase, protease, etc.) within the World Health Organization Anatomical Therapeutic Chemical classification:

• A — Alimentary Tract and Metabolism
• A09 — Digestives, including enzymes
• A09AA — Enzyme preparations
• A09AA02 — Multienzymes, including lipase, protease, and related digestive enzymes

This category includes combinations of digestive enzymes. Combinations that also contain non-enzyme active agents may be assigned to another ATC subgroup depending on the composition and intended therapeutic use.atcddd.fhi

A09AA02 is a heterogeneous pharmacological category rather than a single chemical entity. Preparations may contain pancreatic enzyme mixtures, microbial enzymes, fungal enzymes, plant-derived enzymes, or other defined enzyme combinations. The major enzymatic components commonly include:

• Lipase, which hydrolyses dietary triglycerides into fatty acids and monoglycerides.
• Protease, which degrades proteins into peptides and amino acids.
• Amylase, which converts starch and other polysaccharides into smaller carbohydrate fragments.
• Additional enzymes, depending on the formulation, that may contribute to digestion of lactose, complex carbohydrates, proteins, fats, or other dietary substrates.

The principal pharmacological action of conventional multienzyme products is local within the gastrointestinal lumen. Their purpose is to supplement or replace digestive activity, reduce consequences of impaired digestion, and improve nutrient breakdown before absorption. Pancreatic enzyme replacement therapy is the most clinically important example of this therapeutic principle, particularly in exocrine pancreatic insufficiency caused by conditions such as cystic fibrosis, chronic pancreatitis, pancreatic surgery, pancreatic obstruction, or selected gastrointestinal disorders.

Enteric-coated formulations are often used for pancreatic enzyme preparations. Their design protects enzymes from acid-mediated degradation in the stomach and promotes release in the upper small intestine, where the physiological conditions are more suitable for enzyme activity. Other products, especially non-prescription digestive supplements, may use uncoated capsules, tablets, powders, or liquids with more variable stability and activity.

Because the class includes diverse enzyme sources and combinations, clinical efficacy, dosage, safety, allergenicity, regulatory quality, and lactation suitability cannot be assumed to be identical for all A09AA02 products.

Toxicological Profile

The general toxicological profile of oral multienzyme preparations is shaped by their predominantly local gastrointestinal activity. Enzymes are generally proteinaceous biological molecules that act on food substrates in the gastrointestinal tract. After oral administration, they may be inactivated by gastric acid, degraded by endogenous digestive processes, or act locally before being eliminated. Intact systemic absorption is generally expected to be limited.

At recommended doses, adverse effects are usually gastrointestinal and may include:

• Abdominal pain, discomfort, cramping, or distension.
• Nausea or vomiting.
• Diarrhoea, constipation, altered stool frequency, or abnormal stools.
• Flatulence, bloating, or dyspeptic symptoms.
• Perianal irritation in some circumstances, especially where enzyme-containing material contacts the skin.
• Local oral irritation if capsules are chewed, opened inappropriately, or retained in the mouth.

Hypersensitivity reactions are an important product-specific concern. Pancreatic enzyme products are commonly derived from porcine pancreatic tissue, whereas other multienzyme products may be microbial, fungal, plant-derived, or mixed-source preparations. Allergy or sensitization can occur in susceptible individuals. Patients with a known relevant allergy, including an allergy to porcine proteins, fungal material, microbial enzymes, or a formulation excipient, require careful product selection and clinical assessment.

Pancreatic enzyme replacement therapy carries a rare but clinically important high-dose toxicity concern: fibrosing colonopathy. This condition involves colonic fibrosis and possible stricture formation. It has been associated particularly with prolonged, high-dose pancreatic enzyme therapy, most notably in children with cystic fibrosis. Doses exceeding 6,000 lipase units/kg per meal have been associated with colonic strictures in children, while regulatory product information recommends caution above 2,500 lipase units/kg per meal or 10,000 lipase units/kg per day.ncbi.nlm.nih+1

Symptoms that may suggest a serious gastrointestinal complication include persistent or severe abdominal pain, intestinal obstruction symptoms, bloody diarrhoea, significant change in bowel function, poor weight gain, or unexplained gastrointestinal deterioration. These require prompt medical evaluation. This risk is not appropriately extrapolated to short-term, low-dose, non-pancreatic digestive-enzyme products, but it is highly relevant to prescribed pancreatic enzyme replacement regimens.

Some pancreatic enzyme products may also be associated with elevations in uric acid, particularly in patients receiving high doses or those with gout, hyperuricaemia, or impaired renal function. The clinical relevance depends on the product, cumulative enzyme dose, renal function, and patient-specific metabolic risk.

Non-prescription multienzyme supplements deserve special caution. They may contain combinations of enzymes with herbs, probiotics, betaine hydrochloride, bile salts, acidifying agents, sugars, alcohol-containing liquid vehicles, vitamins, minerals, or other compounds. Enzyme activity may be expressed differently between products, and the stated composition may not predict biological activity or product quality. Such products should not be assumed to be equivalent to licensed pancreatic enzyme replacement medicines.

Lactation Pharmacology and Infant Exposure

Direct human milk pharmacokinetic data for the entire A09AA02 class are limited. Nonetheless, conventional oral multienzyme preparations have pharmacological properties that generally predict low exposure of the breastfed infant.

Most digestive enzyme preparations act in the maternal gastrointestinal tract and have limited intact systemic bioavailability. Their proteinaceous nature means that they are susceptible to degradation in the gastrointestinal tract. Therefore, only negligible quantities would ordinarily be expected to reach maternal plasma and become available for transfer into breast milk.

If trace amounts of enzyme-derived protein were present in milk, the breastfed infant would be expected to digest it in the gastrointestinal tract. This makes clinically meaningful systemic infant absorption improbable. In addition, breast milk naturally contains biologically active proteins and enzymes, although this fact should not be interpreted as direct proof that each medicinal enzyme formulation is safe or that it has equivalent pharmacokinetics.

LactMed considers pancrelipase acceptable for use during breastfeeding on the basis of expert opinion. This is clinically relevant because pancrelipase is a representative multienzyme pancreatic preparation that contains lipase, protease, and amylase activity. However, the available statement should not be generalized without qualification to every enzyme mixture, particularly products with additional pharmacologically active components or unregulated supplement formulations.datahub.hhs

Factors that may alter the lactation assessment include:

• The exact enzyme source, composition, and potency.
• Whether the product is a regulated medicinal product or a dietary supplement.
• The presence of non-enzyme active ingredients, including acidifying agents, bile components, herbal extracts, probiotics, or pharmacologically active adjuncts.
• Maternal dose, duration of therapy, and underlying disease.
• The infant’s gestational age, clinical stability, allergy history, and gastrointestinal status.

From a lactation perspective, the underlying maternal condition may be more important than milk transfer. Untreated exocrine pancreatic insufficiency can contribute to maldigestion, malabsorption, inadequate energy intake, weight loss, fat-soluble vitamin deficiency, and poor maternal nutritional status. These factors may impair maternal health and can complicate the maintenance of breastfeeding. Effective enzyme replacement therapy may therefore support rather than hinder successful lactation when clinically indicated.

Lactological Safety Assessment and Clinical Recommendations

Conventional oral multienzyme preparations, including properly prescribed pancreatic enzyme replacement therapy, are generally considered compatible with breastfeeding when clinically indicated. The low expected maternal systemic absorption, limited plausibility of transfer into milk, and likely gastrointestinal digestion of any trace enzyme protein by the infant support a low risk of clinically relevant infant exposure.

Breastfeeding should not be routinely interrupted because of maternal treatment with a standard enzyme-only A09AA02 product. For mothers with exocrine pancreatic insufficiency, chronic pancreatitis, cystic fibrosis, post-pancreatectomy malabsorption, or another established indication for pancreatic enzyme replacement, discontinuing effective treatment may create substantially greater maternal risk than continuing therapy during lactation.

Clinical recommendations

• Continue prescribed pancreatic enzyme replacement therapy during breastfeeding when it is required to maintain digestion, nutritional status, and control of the underlying maternal disease.
• Prefer a licensed, well-characterized enzyme preparation with a defined enzyme content and established dose instructions.
• Use the lowest effective dose that adequately controls symptoms and supports nutritional adequacy; do not reduce clinically necessary replacement therapy solely because of breastfeeding.
• Ensure correct administration of enteric-coated products; capsules should generally not be crushed or chewed because this can damage the formulation and expose oral mucosa to active enzymes.
• Evaluate the complete formulation before use during breastfeeding. Do not infer safety of a multienzyme product from enzyme content alone if it includes herbs, acids, bile salts, alcohol, high-dose vitamins, probiotics, or other active constituents.
• Avoid non-standardized supplements when a regulated medicinal alternative is available, particularly in mothers of newborn, premature, or medically fragile infants.
• Monitor nutritional status in mothers with pancreatic insufficiency, including body weight, dietary intake, hydration, symptom control, and clinically appropriate micronutrient assessment.
• Review high-dose regimens carefully and investigate persistent abdominal pain, bowel obstruction symptoms, rectal bleeding, or major changes in bowel habits because of the rare association between prolonged high-dose pancreatic enzymes and fibrosing colonopathy.ncbi.nlm.nih+1
• Obtain individualized specialist advice if the mother has a history of severe porcine protein allergy, fungal or microbial enzyme allergy, gout, hyperuricaemia, renal impairment, active severe gastrointestinal disease, or prior fibrosing colonopathy.

Infant monitoring

For healthy full-term infants, routine additional monitoring is not usually required when the mother receives an enzyme-only multienzyme preparation at usual therapeutic doses. Practical observation is nevertheless appropriate.

Caregivers should seek paediatric or lactation advice if the infant develops persistent diarrhoea, recurrent vomiting, rash, wheeze, feeding refusal, unusual irritability, or poor weight gain. These findings are unlikely to result from exposure to maternal digestive enzymes through milk alone and should prompt evaluation for other more probable causes, including infection, cow’s milk protein allergy, feeding difficulty, or an independent gastrointestinal disorder.

Overall conclusion

A09AA02 multienzyme products include combinations of digestive enzymes such as lipase, protease, and amylase. They are pharmacologically heterogeneous but generally act locally in the gastrointestinal tract, have low expected systemic absorption, and are unlikely to produce clinically meaningful exposure in a breastfed infant.atcddd.fhi

For standard enzyme-only preparations, including clinically necessary pancreatic enzyme replacement therapy, breastfeeding can usually continue without interruption. Pancrelipase is regarded as acceptable during breastfeeding by LactMed expert opinion. The principal lactological caution concerns complex combination products and non-standardized supplements, for which all added ingredients must be assessed separately. Maternal nutritional adequacy and appropriate control of the underlying digestive disorder should remain central clinical priorities.datahub.hhs